Robocath, which is developing robotic-assisted technology for cardiovascular diseases, has collected capital from investors including TUS-Holdings.

Robocath, a France-based developer of a cardiovascular disease treatment system developer, raised €40m ($43.4m) in a series C round yesterday backed by Luxembourg CLIIF, an investment fund managed by the Tsinghua University-affiliated TUS-Holdings,
Medical device manufacturer MicroPort Scientific led the round, which also included regional investment vehicles Go Capital, NCI and Normandie Participations, and national investment funds M Capital and Supernova Invest.
Financial services firm Crédit Agricole’s Unexo and Crédit Agricole Normandie units filled out the round with…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in